References for localised disease

1. Armstrong BK, Kicker A. Cutaneous melanoma. Cancer 15. Surv 1994; 19-20:219-40.

2. Mackie RM, Hole D, Hunter JA et al. Cutaneous malignant melanoma in Scotland: incidence survival and mortality 16. 1979-1994. BMJ 1997;315:1117-21.

3. Giles GG, Armstrong BK, Burton RC et al. Has mortality from melanoma stopped rising in Australia. Analysis of trends between 1931 and 1994. BMJ 1996;312:1121-5. 17.

4. National Cancer Institute of Canada. Canadian Cancer Statistics 1997. National Cancer Institute of Canada: Toronto, 1997.

5. Holme SA. Malinovsky K, Roberts DL. Malignant melanoma in South Wales: changing trends in presentation (1986-98). Clin Exp Dermatol 2001;26:484-9. 18.

6. Breslow A. Thickness, cross sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann

Surg 1970;172:902-8. 19.

7. Balch CM, Soong SJ, Shaw HM et al. An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton Anilton GW, Sober AL

Soong S, eds. Cutaneous Melanoma, 2nd ed. New York: 20.

Ellis Horwood, 1992.

8. Friedmann RJ, Rigel DS, Silverman M, Kopf AW. The continued importance of the early detection of malignant 21. melanoma. CA Cancer J Clin 1991;41:201-26.

9. Healsmith MF, Bourke JF, Osborne JE, Graham Brown RAC. An evaluation of the revised seven-point checklist for the diagnosis of cutaneous malignant melanoma. Br J 22.

Dermatol 1994; 130:48-50.

10. Nachbar F, Stolz W, Merkle T et al. The ABCD rule of dermatoscopy. High prospective value in the diagnosis of 23. doubtful melanocytic skin lesions. J Am Acad Dermatol 1994;30:4:551-9.

Lederman JS, Sober AJ. Does biopsy type influence survival in clinical stage I cutaneous melanoma. J Am Acad Dermatol 1985;13:983-7.

Lees VC, Briggs JC. Effect of an initial biopsy on prognosis in stage I invasive cutaneous malignant melanoma; review of 1086 patients. Br J Surg 1991;71:1108-10. Bong JL, Herd RM, Hunter JAA. Incisional biopsy and melanoma prognosis. J Am Acad Dermatol 2002;46:690-4. Austin JR, Byers RM, Brown WD, Wolf P. Influence on biopsy on the prognosis of cutaneous melanoma of the head and neck. Head Neck 1996;18:107-17. Veronesi U, Cascinelli N. Narrow excision (1cm margin); a safe procedure for thin cutaneous melanoma. Arch Surg 1991;126:438-41.

Balch CM, Urist MM, Karakousis CP et al. Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1-4 mm): result of a multi-institutional randomised surgical trial. Ann Surg 1993;218:262-7. Cohn-Cedermark G, Rutqvist LE, Andersson R et al. Long term results of a randomised study by the Swedish Melanoma Study Group on 2 cm versus 5 cm resection margins for patients with cutaneous melanoma with a tumour thickness of 0-8mm-2-0mm. Cancer 2000;89: 1495-1501.

Heaton KM, Sussman JJ, Gershanwald JE et al. Surgical margins and prognostic factors in patients with thick (> 4mm) primary melanoma. Ann Surg Oncol 1998;5:322-8. Guerry D IV, Synnestvedt M, Elder DE, Schultz D. Lessons from tumour progression; the invasive radial growth phase of melanoma is common, incapable of metastasis, and indolent. J Invest Dermatol 1993;100:3428-55. Sober AJ, Tsu-yi Chang, Duvic M et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001;45:579-86.

Mackie RM. Melanocytic naevi and malignant melanoma. In: Champion RH, Burton JL, Burns DA, Breathnach SM, eds. Textbook of Dermatology, 6th ed. Oxford: Blackwell Science 1998;Vol. 2:1741-50.

Pitman GH, Kopf AW, Bart RS et al. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1979;5:727-37.

Coleman WP III, Davis RS, Reed RJ et al. Treatment of lentigo maligna and lentigo maligna melanoma. J Dermatol Surg Oncol 1980;6:476-9.

24. Cohen LM, McCall MW, Zax RH. Mohs' micrographic surgery for lentigo maligna and lentigo maligna melanoma: a follow up study. Dermatol Surg 1998:24: 673-7.

25. Kufflik EG, Gage AA. Cryosurgery for lentigo maligna. J Am Acad Dermatol 1994;31:75-8.

26. Bohler-Sommerregger K, Schuller-Petrovic S, Knobner R et al. Reactive lentiginous hyperpigmentation after cryosurgery for lentigo maligna. J Am Acad Dermatol 1992;27:523-6.

27. Arma-Szlachcic M, Ott F, Storck H. Zur Strahlentherapie der melanotischen Pracancerosen. Hautartz 1970;21: 505-8.

28. Tsang RW, Liu F, Wells W, Payne DG. Lentigo maligna of the head and neck; results of treatment by radiotherapy. Arch Dermatol 1994;130:1008-12.

29. Litwin MS, Kremetz ET, Mansell PW, Reed RJ. Topical treatment of lentigo maligna with 5-fluorouracil. Cancer 1995;3:721-33.

30. Rivers JK, McCarthy WH. No effect of topical tretinoin in lentigo maligna (letter). Arch Dermatol 1991; 127:129.

31. Nazzoro-Porro M, Passi S, Zina G et al. Ten years' experience of treating lentigo maligna with topical azelaic acid. Acta Derm Venereol 1989;143(Suppl.):49-57.

32. Cox NH, Aitchision TC, Sirel JM, MacKie RM. Comparison between lentigo maligna melanoma and other histogenic types of malignant melanoma of the head and neck. Scottish Melanoma Group. Br J Cancer 1996;73:940-4.

33. Schmid-Wendtner MH, Brunner B, Konz B et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000;43:477-82.

34. Mahendran R, Newton-Bishop JA. Survey of UK current practice in the treatment of lentigo maligna. Br J Dermatol 2001;144:71-6.

35. Balch CN, Soong SJ, Bartolucci AA et al. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996;224:225-63.

36. Cascinelli N, Moradite A, Santinorrii M et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998;351:793-6.

37. Sim PH, Taylor WF, Ivins JC et al. A prospective randomised study of the efficacy of routine elective lymphadenectomy in management of malignant melanoma: preliminary results. Cancer 1978;41:948-56.

38. Veronesi U, Adamus J, Bandiera DC et al. Inefficacy of immediate node dissection in stage I melanoma of the limbs. N Engl J Med 1977;297:627-30.

39. Baas PC, Schrafferdt KH, Koops H et al. Groin dissection in the treatment of lower extremity melanoma: short term and long term morbidity. Arch Surg 1992;127:281-6.

40. Morton DL, Wen D-R, Wong JH et al. Technical details of intra-operative lymphatic mapping for early stage melanoma. Arch Surg 1992;127:392-9.

41. Morton DL, Thompson JF, Essner R et al. Validation of the accuracy of intra-operative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma. Ann Surg 1999;230:453-65.

42. Balch CM, Buzard AC, Soong SJ et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19:3635-48.

43. Gershenwald JE, Thompson W, Mansfield PF et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage 1 or 11 melanoma patients. J Clin Oncol 1999;17:976-83.

44. Rayatt SS, Hettiaratchy SP. Having this biopsy gives psychological benefits (letter). BMJ 2000;321:1285.

45. Jansen L, Nieweg OE, Peterse JL, Hoefnagel CA, Ohnos

RA, Kroon BBR. Reliability of sentinel lymph node biopsy for staging melanoma. Br J Surg 2000;87:484-9.

46. Kirkwood JM, Strawderman MH, Ernstoff MS et al. Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma: The Eastern Co-operative Oncology Group Trial. Est. 1684. J Clin Oncol 1996;14:7-17.

47. Kirkwood JM, Ibrahim JG, Sondak VK et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of Intergroup trial 1690/S9111/C9190. J Clin Oncol 2000; 18:2444-58.

48. Kirkwood JM, Ibrahim JG, Sosman JA et al. High-dose interferon alfa 2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of Intergroup trial E1694/S9512/C509801. J Clin Oncol 2001; 19:2370-80.

49. Grob JJ, Dreno B, de la Salmoniere P et al. Randomised trial of interferon alfa -2b as adjuvant therapy in resected primary melanoma thicker than 1-5 mm without clinically detectable node metastases. French Co-operative Group on Melanoma. Lancet 1998;351:1905-10.

50. Perhamberger H, Peter Soyer H, Steiner A et al. Adjuvant interferon alfa-2b in resected primary stage II cutaneous melanoma. J Clin Oncol 1998;16:1425-9.

51. Hillner BE, Kirkwood JM, Atkins MB, Johnson ER, Smith TJ. Economic analysis of adjuvant interferon Alfa-2B in high risk melanoma based on projections from Eastern Cooperative Oncology Group 1684. J Clin Oncol 1997;15:2351-8.

52. Lafuma A, Dreno B, Delauney M et al. Economic analysis of adjuvant therapy with interferon alfa-2a in stage II malignant melanoma. Eur J Oncol 2001;37:369-75.

Was this article helpful?

0 0
10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment